Trial Profile

Effect and Safety of Semaglutide 2.4 mg Once-weekly on Weight Management in Subjects With Overweight or Obesity.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 02 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Semaglutide (Primary)
Indications Obesity
Focus Registrational; Therapeutic Use
Acronyms STEP 7
Sponsors Novo Nordisk

Most Recent Events

01 May 2025 Results (n=195) demonstrating beneficial effects of semaglutide 2.4 mg versus placebo, supporting its use in an adult Chinese population with overweight or obesity will be published in the Diabetes, Obesity and Metabolism
19 Sep 2022 Status changed from active, no longer recruiting to completed.
12 Jan 2022 Planned End Date changed from 12 Oct 2022 to 23 Aug 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com